|1.||Ahdieh, Harry: 14 articles (05/2010 - 06/2004)|
|2.||Ma, Tina: 7 articles (05/2010 - 07/2004)|
|3.||Gould, Errol M: 6 articles (04/2013 - 02/2009)|
|4.||Kaasa, Stein: 3 articles (04/2012 - 02/2010)|
|5.||Dale, Ola: 3 articles (04/2012 - 02/2010)|
|6.||Kerwin, Rosemary: 3 articles (10/2008 - 01/2007)|
|7.||Rauck, Richard: 3 articles (10/2008 - 01/2007)|
|8.||Krugner-Higby, Lisa: 3 articles (10/2004 - 06/2003)|
|9.||Heath, Timothy D: 3 articles (10/2004 - 06/2003)|
|10.||Centers for Disease Control and Prevention (CDC): 2 articles (05/2015 - 01/2013)|
08/01/2008 - "Oxymorphone provides excellent pain relief for significant pain, with typical opioid side effects that are usually mild or moderate in intensity. "
12/01/2005 - "The mean SPID score was significantly greater in the oxymorphone IR group, showing greater pain relief, compared with the placebo group (least squares mean difference +/- standard error, 76.9+/-28.09; 95% confidence interval, 21.26-132.59; P=.007). "
11/01/2004 - "All oxymorphone IR doses were superior for providing pain relief for 8 h (P < 0.05), with a significant analgesic dose response (P < 0.001). "
10/01/2008 - "Oxymorphone ER provided effective pain relief from moderate to severe chronic pain in opioid-naive patients. "
06/01/2003 - "In conclusion, LE oxymorphone was effective in treating visceral pain associated with intestinal surgery in rats. "
03/01/2006 - "A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee."
03/01/2006 - "This study compared the analgesic efficacy, dose response, and tolerability of 3 doses of oxymorphone ER given every 12 hours with those of placebo in patients with pain related to osteoarthritis (OA) of the hip or knee. "
03/01/2005 - "Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study."
08/01/2010 - "This post hoc analysis of oxymorphone ER consumption in osteoarthritis pain vs pain report showed that most dose changes occurred during an initial "titration period" as defined. "
09/01/2005 - "To compare oxymorphone extended release (ER) and placebo on indices of pain, function, and safety in patients with chronic osteoarthritis (OA) pain. "
|3.||Low Back Pain (Lumbago)
01/01/2007 - "A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain."
02/01/2009 - "This study assessed the potential effects of age, sex, and prior opioid use on the response to oxymorphone extended release (ER) in patients with moderate to severe chronic low back pain. "
01/01/2005 - "Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study."
08/01/2010 - "To evaluate the influence of age, sex, and previous opioid experience on the likelihood of successfully titrating opioid-naive and experienced patients with chronic low back pain (CLBP) to an effective and well-tolerated dose of oxymorphone extended release (ER). "
08/01/2010 - "Factors affecting acceptability of titrated oxymorphone extended release in chronic low back pain - an individual patient analysis."
05/01/2010 - "Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer."
02/01/2010 - "Limited evidence suggests that oxymorphone is effective for pain control in patients with cancer. "
05/01/2010 - "Patients with cancer pain who had participated in two short-term crossover comparator trials of oxymorphone ER: one open-label and one double-blind randomized. "
05/01/2008 - "Six published randomized controlled trials and three published open-label studies evaluated the efficacy and safety of oxymorphone ER for chronic cancer or noncancer pain. "
05/01/2010 - "In these patients with pain related to cancer, oxymorphone ER was generally well tolerated and provided stable long-term pain control."
06/01/2007 - "This study assessed the efficacy and tolerability of multiple fixed doses of oxymorphone IR in the treatment of acute postoperative pain after abdominal surgery. "
06/01/2007 - "Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial."
06/01/2003 - "A single administration of LE oxymorphone hydrochloride was as effective for relief of postoperative pain in rats (P = 0.18), as were multiple (q4 h or q8 h) injections of 0.3 mg/kg of the standard pharmaceutical preparation. "
08/01/2014 - "It was concluded that a single administration of TFS was safe and noninferior to repeated injections of oxymorphone for the control of postoperative pain over 4 days at the dose rates of both formulations used in this study."
05/01/2008 - "Two published studies evaluated the efficacy and safety of oxymorphone IR in patients with moderate to severe postoperative pain and demonstrated that it provides rapid and effective analgesia and is generally well tolerated. "
|2.||Morphine (MS Contin)
|3.||Opioid Analgesics (Opioids)
|5.||oxymorphine HCl (Opana)
|10.||Bupivacaine (Bupivacaine Hydrochloride)